Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab with Radiotherapy and Temozolomide for Glioblastoma
NCT03388372Phase 2Completed
- Start
- Aug 2010
- Primary completion
- Mar 2017
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab in glioblastoma (GBM). Started Aug 2010; status: completed.
02
Drugs
nimotuzumab
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT03388372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03388372.